Semma is a privately held biotechnology company that uses stem cell-derived human islets for Type 1 diabetes treatments. It will become a separate operating subsidiary of Vertex, with CEO Bastiano Sanna joining Vertex as president of Semma. Douglas Melton, the scientific founder of Semma, will stay as chair of its scientific advisory board while guiding on research and development.
The acquisition is expected to close in Q4 subject to conditions including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Price: 181.50, Change: +1.48, Percent Change: +0.82
|Aesthetic Medical Eyes Up to $33 Million in US IPO|
|Market Chatter: ExxonMobil Signs Natural Gas Agreeme...|
|ExxonMobil Partners With ONGC to Study PEL blocks in...|
|China Threatens Countermeasures If US House Approves...|
|--China Threatens Retaliation If US Passes Hong Kong...|